Johns Hopkins researchers are working closely with tribal leaders, adolescent girls, and their parents, as well as with teachers and health care workers, to put helpful resources directly into the hands of Native American girls.
Johns Hopkins engineers are tackling one of today’s most complex and important technological challenges: how to ensure the safety of autonomous systems, from self-driving cars and aerial delivery drones to robotic surgical assistants.
According to researchers at Johns Hopkins Medicine, the Massachusetts Institute of Technology, and Rice University, silicone breast implants with a smoother surface design have less risk of producing inflammation and other immune system reactions than those with more roughly textured coatings.
By launching AbMeta Therapeutics, a startup aimed at developing anti-metastatic therapies based on engineered antibodies, Denis Wirtz has served as a real-life example of the high value that Johns Hopkins places on entrepreneurship.
Johns Hopkins environmental engineer Carsten Prasse discusses a new approach to assessing water quality with the potential to aid the creation of engineering and policy approaches that are tailored toward individual water systems.
Johns Hopkins researchers are collaborating to design an ultrasonic, photoacoustic endovaginal imaging device that monitors the fetal brain during labor and can more accurately predict serious fetal distress.
Johns Hopkins biomedical engineering professor Sri Sarma and neurologist Khalil Husari have developed an EEG analytics algorithm that uses at-rest data to build a “heat map” of a patient’s brain activity that a doctor can then quickly and definitively interpret.
A team of researchers is developing a low-cost hand-held device for cataract surgery that allows for fragmentation and removal of all grades of cataracts through a very small incision, giving patients in all settings access to optimal surgical outcomes.
A new particle assembly technology created by Johns Hopkins engineers in partnership with experts from a biotechnology company is making it easier and more cost-efficient to produce viral vectors: engineered viruses that have been used to modify therapeutic cells to treat congenital and acquired diseases.